Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0005684 (bladder cancer)
 16,431 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Using the tritiated-proline microcytotoxicity assay with cultured target cells, we tested a large series of melanoma, breast cancer, and bladder cancer patients for the presence of cell-mediated immunity. Specific, disease-related activity was infrequently observed, since the patients' lymphocytes exhibited selective activity against both disease-related and non-disease-related target cells. Most normal controls also demonstrated selective activity against these target cells. Neither the length of time the target cells had been cultured in vitro nor technical aspects of the assay, including the lymphocyte preparation methods, seemed to account for our results. We concluded that the experimental design of these tests may be the critical factor responsible for many of the disparate results being observed in different laboratories.
J Natl Cancer Inst 1975 Dec
PMID:Cellular microcytotoxicity in human tumor systems: analysis of results. 5 36

The use of recognised carcinogens in the rubber industry before 1950 led to the introduction of screening progammes offering urinary cytology to workers who had been exposed. Publicity given to the introduction of these programmes and to individual claims for compensation have increased medical practitioners' awareness of a relationship between work and the industry and the subsequent development of bladder cancer. In this study 27 rubber workers and 88 controls registered in 1966 and 1967 with bladder cancer have been followed. A comparison of their death-rates and of the relative frequency of bladder cancer recorded on the death certificates should indicate whether cytological screening or doctors' awareness might explain a recent rise in the bladder-cancer death-rate in this industry. Since the proportions of rubber workers and controls who died before 1976 were similar (74% and 73% respectively) and bladder cancer was mentioned with similar frequence on their death certificates (80% and 83% respectively) neither screening nor doctor's awareness would appear to have an important influence.
 ...
PMID:Bladder cancer in rubber workers. Do screening and doctors' awareness distort the statistics? 5 1

The results of treating 50 patients with bladder cancer with radiotherapy over a three-year period are evaluated. Ten cases (20 per cent) were treated for palliation. Sixteen of 40 patients treated with intent of cure are considered well with no evidence of disease. Six additional cases were salvaged by further surgery. Another 7 patients died because of natural causes or distant metastases with good local control of the primary cancer postradiotherapy. The remaining 11 cases were considered failures, all died except one living with disease. These patients could not be saved by further surgery primarily because they were not medically fit. Six of twelve cases (50 per cent) survived three years and 19 of 31 cases (61 per cent) survived for one year free of disease. Reasons for possible failures are discussed.
 ...
PMID:Role of radiation therapy in cancer of bladder. 6 39

An epithelioid cell line (PS-1) has been established from a transitional cell cancer derived from human urinary bladder. Subcutaneous injection of the epithelioid cells into weanling athymic nude mice induced solid tumors histologically similar to the original tumor. A cell line was also established from a tumor induced in the athymic nude mouse (PS-1, T-1). Both cell lines exhibited essentially identical growth characteristics and formed a monolayer growth of epithelioid cells in culture. Electron microscopic studies confirmed epithelioid morphology. No fibroblastoid elements were observed. Chromosomal analysis revealed heteroploidy with persistent marker chromosomes; all cells contained a Y chromosome. The presence of tumor-specific antigen(s) in PS-1 cells was suggested by microcytotoxicity assays with peripheral allogeneic lymphocytes from other transitional cancer cell patients. Sera of urinary bladder cancer patients reacted with nuclear antigens of the established cells.
 ...
PMID:Establishment and characterization of a new human urinary bladder carcinoma cell line (PS-1). 8 14

An antiserum against T24 was raised in rabbits. One serum that was tested by complement-dependent cytotoxicity and absorption analysis appeared to distinguish functionally between bladder cancer cell lines and other cell lines.
Natl Cancer Inst Monogr 1978 Dec
PMID:Detection of antigens on transitional cell carcinoma with a xenogeneic antiserum. 8 68

A population of workers exposed to bladder carcinogens has been studied by comparing their immunoreactivity against bladder cancer cells and against a control cancer cell with that found in normal individuals and in patients with bladder cancer. Data are presented which indicate equivalent increases in specific reactivity against bladder cancer cells in clinically normal carcinogen-exposed workers and in patients with bladder cancer. Increases in reactivity are related to degree of exposure and also to early malignant changes in the urothelium. This indicates that immune recognition of tumour antigens does occur before development of overt malignancy.
Int J Cancer 1979 Apr 15
PMID:Immunosurveillance in pre-malignant occupational bladder disease. 8 24

This paper reports the preliminary results of an ongoing clinical trial in patients with category T1 bladder cancer who are randomized after transurethral resection to receive either thiotepa, VM-26, or no treatment. While there are no significant differences between the three treatment groups with respect to the time until first recurrence, thiotepa has significantly reduced the recurrence rate as compared to either VM-26 (P = 0.03) or no treatment (P = 0.04) among the 215 patients for whom follow-up information is currently available.
Recent Results Cancer Res 1978
PMID:Adjuvant therapy of T1 bladder carcinoma: preliminary results of an EORTC randomized study. 11 22

Eighty one patients (59 females, 22 males) with advanced solid tumors were treated with Adriamycin in doses of 40 mg/m2 body surgace daily, in two days cycles, with resting periods of 3 weeks. Overall response rate was 46% (37/81). In breast cancer response rate was 56% (13/23) and in ovarian cancer 48% (13/27). In various other tumors remission was observed in soft tissue sarcomas (3/8), thyroid cancer (1/7), osteogenic sarcoma (1/4), oesophageal cancer (2/4), lung cancer (2/4), bladder cancer (1/2) and hepatoma (1/2). In breast cancer patients, 2-7 month remission duration was observed (M equal to 4.5 month) and in ovarian cancer 1.5-5 month (M equal to 3.2 month). Adriamycin was also applied intrapleurally in 31 patients with malignant pleural effusions with a low response rate (26%). This modified schedule of Adriamycin administration showed a high antitumor activity in breast and ovarian cancer and in soft tissue sarcomas. Squamous cell carcinoma of the esophagus was also sensitive to Adriamycin therapy. The very low rate of myelosuppression and oral ulceration showed the decreased toxicity of this Adriamycin administration schedule.
Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1977
PMID:Modified administration schedule of adriamycin in solid tumors. 14 May 42

In a comparative study of tryptophan metabolism and urinary excretion of nucleic acid derivatives (including beta-aminoisobutyric acid, 7-methylguanine, pseudouridine, and urate) in 12 male bladder cancer patients, the excretion of pseudouridine and 7-methylguanine decreased significantly after an oral dose of 2 g L-tryptophan. A similar decrease occurred after an oral nicotinamide load of 50 mg four times a day, which indicated a possible common mode of action of tryptophan and nicotinamide. No definite resolution could be made as to the causal mechanism for the observed descrase in RNA turnover.
J Natl Cancer Inst 1977 Sep
PMID:Effect of tryptophan and nicotinamide loads on urinary excretion of RNA metabolites by bladder cancer patients. 14 44

The authors present an analysis of the data on 281 primarily recognized patients with cancer of the urinary bladder in Grodno Province 1968--1974. Among all these patients 49.5% were recognized 1 year and longer following the initial clinical manifestations of the disease. In every fifth case there was a far-advanced process. The causes of late recognition are as follows: underestimation of a tainsiet hematuria by patients, and in a number of cases the absence of oncological vigilance among general practitioners in the treatment of patients showing hematuria. To improve the early diagnosis of the bladder cancer, it is suggested to differentiate cancer high-risk groups. This contingent should be periodically examined by a specialist with prophylactic purposes. Moreover, an attention is paid to the necessity of a detailed urological examination of all persons with hematuria, or who showed it previously.
 ...
PMID:[Ways to improve the early detection of bladder cancer patients (based on Grodno Province data)]. 15 Jan 29


1 2 3 4 5 6 7 8 9 10 Next >>